Researches and develops pharmaceutical products for psychiatric and neurological disorders. Now — the numbers.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Every year shown ended in profit.
The gap is $1.3B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 11.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 10% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.18 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.